Next Article in Journal
In silico Designed Ebola Virus T-Cell Multi-Epitope DNA Vaccine Constructions Are Immunogenic in Mice
Previous Article in Journal
Reply to “Comment on Effectiveness of a Group B Outer Membrane Vesicle Meningococcal Vaccine in Preventing Hospitalization from Gonorrhea in New Zealand: A Retrospective Cohort Study, Vaccines, 2019, 1, 5; doi:10.3390/vaccines7010005”
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 7
Issue 1
10.3390/vaccines7010033
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line

by
Pedro M. Folegatti
1,*,
Duncan Bellamy
1,
Amy Flaxman
1,
Catherine Mair
1,
Chris Ellis
2,
Raquel L. Ramon
1,
Fernando Ramos Lopez
1,
Celia Mitton
1,
Megan Baker
1,
Ian Poulton
1,
Alison Lawrie
1,
Rachel Roberts
1,
Angela Minassian
1,
Katie J. Ewer
1,
Thomas G. Evans
2,
Adrian V. S. Hill
1 and
Sarah C. Gilbert
1
1
The Jenner Institute, University of Oxford, ORCRB, Roosevelt Drive, Oxford OX3 7DQ, UK
2
Vaccitech Ltd., The Schrodinger Building, 2nd Floor, Oxford Science Park, Heatley Road, Oxford OX4 4GE, UK
*
Author to whom correspondence should be addressed.
Vaccines 2019, 7(1), 33; https://doi.org/10.3390/vaccines7010033
Submission received: 22 January 2019 / Revised: 27 February 2019 / Accepted: 18 March 2019 / Published: 22 March 2019
Browse Figures
Versions Notes

Abstract

Seasonal influenza infections have a significant global impact leading to increased health and economic burden. The efficacy of currently available seasonal influenza vaccines targeting polymorphic surface antigens has historically been suboptimal. Cellular immune responses against highly conserved Influenza A virus antigens, such as nucleoprotein (NP) and matrix protein-1 (M1), have previously been shown to be associated with protection from disease, whilst viral-vectored vaccines are an effective strategy to boost cell-mediated immunity. We have previously demonstrated that MVA encoding NP and M1 can induce potent and persistent T cell responses against influenza. In this Phase I study, we evaluated the safety and immunogenicity of MVA-NP+M1, which was newly manufactured on an immortalized cell line, in six healthy adult participants. The vaccine was well-tolerated with only mild to moderate adverse events that resolved spontaneously and were comparable to previous studies with the same vaccine manufactured in chick embryo fibroblasts. A significant increase in vaccine-specific T cell responses was detected seven days after immunization and was directed against both antigens in the vector insert. This small Phase I study supports progression of this vaccine to a Phase IIb study to assess immunogenicity and additional protective efficacy in older adults receiving licensed seasonal influenza vaccines.
Keywords: influenza; heterosubtypic vaccine; safety; immunogenicity; viral vectors influenza; heterosubtypic vaccine; safety; immunogenicity; viral vectors

Share and Cite

MDPI and ACS Style

Folegatti, P.M.; Bellamy, D.; Flaxman, A.; Mair, C.; Ellis, C.; L. Ramon, R.; Ramos Lopez, F.; Mitton, C.; Baker, M.; Poulton, I.; et al. Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line. Vaccines 2019, 7, 33. https://doi.org/10.3390/vaccines7010033

AMA Style

Folegatti PM, Bellamy D, Flaxman A, Mair C, Ellis C, L. Ramon R, Ramos Lopez F, Mitton C, Baker M, Poulton I, et al. Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line. Vaccines. 2019; 7(1):33. https://doi.org/10.3390/vaccines7010033

Chicago/Turabian Style

Folegatti, Pedro M., Duncan Bellamy, Amy Flaxman, Catherine Mair, Chris Ellis, Raquel L. Ramon, Fernando Ramos Lopez, Celia Mitton, Megan Baker, Ian Poulton, and et al. 2019. "Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line" Vaccines 7, no. 1: 33. https://doi.org/10.3390/vaccines7010033

APA Style

Folegatti, P. M., Bellamy, D., Flaxman, A., Mair, C., Ellis, C., L. Ramon, R., Ramos Lopez, F., Mitton, C., Baker, M., Poulton, I., Lawrie, A., Roberts, R., Minassian, A., Ewer, K. J., Evans, T. G., Hill, A. V. S., & Gilbert, S. C. (2019). Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line. Vaccines, 7(1), 33. https://doi.org/10.3390/vaccines7010033

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop